Scientific Directory
Dr Christopher MONTEMAGNO
Chercheur Post-Doctorant - Equipe Mécanismes de résistance aux thérapies cibléesTel. +377 97 77 44 10
Email : [javascript protected email address]
Thèmes de recherche développés
Etude d'un nouveau facteur impliqué dans l'angiogenèse.
Publications CSM
-
From Malignant Progression to Therapeutic Targeting: Current Insights of Mesothelin in Pancreatic Ductal Adenocarcinoma
Montemagno C, Cassim S, Pouyssegur J, Broisat A, Pagès G
Int J Mol Sci 21(11): 4067 -
Metastatic Heterogeneity of Breast Cancer: Companion and Theranostic Approach in Nuclear Medicine
Montemagno C, Pagès G
Cancers 12(4): 821 -
Resistance to anti-angiogenic therapies: A mechanism depending on the time of exposure to the drugs
Montemagno C, Pagès G
Front Cell Dev Biol 8: 584 -
Soluble forms of PD-L1 and PD-1 as prognostic and predictive markers of sunitinib efficacy in patients with metastatic clear cell renal cell carcinoma.
Montemagno C, Hagege A, Borchiellini D, Thamphya B, Rastoin O, Ambrosetti D, Iovanna J, Rioux-Leclercq N, Porta C, Négrier S, Ferrero J-M, Chamorey E, Pagès G, Dufies M
Oncoimmunology 9:1, 1846901 -
Targeting mesothelin in pancreatic ductal adeno-carcinoma (PDAC)
Montemagno C, Pagès G
J Cell Immunol 2(2): 65-67 -
99mTc-A1 as a Novel Imaging Agent Targeting Mesothelin-Expressing Pancreatic Ductal Adenocarcinoma
Montemagno C, Cassim S, Trichanh D, Savary C, Pouyssegur J, Pagès G, Fagret D, Broisat A, Ghezzi C
Cancers 11(10): 1531